ANPCY - Angle bags a pharma service contract for Crescendo Biologics
2023-04-13 05:00:23 ET
- Liquid biopsy company, ANGLE ( OTCQX:ANPCY ) has signed a contract with a new customer, Crescendo Biologics.
- Crescendo is a UK-based, clinical stage immuno-oncology company with an extensive proprietary pipeline of novel, targeted T cell enhancing Humabody therapeutics.
- Crescendo will use ANGLE's recently launched Portrait Flex assay in its ongoing Phase 1 clinical trial investigating the safety and efficacy of CB307, Crescendo's first-in-class prostate-specific membrane antigen x CD137 half-life extended bispecific, for the treatment of patients with PSMA positive solid tumours.
For further details see:
Angle bags a pharma service contract for Crescendo Biologics